Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology

00:00 / 00:00

Notes

SULFONYLUREAS & MEGLITINIDES
DRUG NAME
First generation: tolbutamide, tolazamide, chlorpropamide
Second generation: glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Glynase)
*High Alert Medications*

repaglinide, nateglinide
*High Alert Medications*

CLASS
Sulfonylureas
Meglitinides
MECHANISM OF ACTION
Inhibit ATP-sensitive K+ channels on pancreatic beta cells → increase insulin secretion → decrease blood glucose levels
INDICATIONS
Type 2 diabetes mellitus
ROUTE(S) OF ADMINISTRATION
PO
SIDE EFFECTS
  • Hypoglycemia
  • Headaches, dizziness, fatigue
  • Weight gain
  • Gastrointestinal disturbances
  • Back pain, arthralgias
  • Skin rash, pruritus
  • Allergic or anaphylactic reactions
  • Second generation sulfonylureas: hepatotoxicity, hematologic side effects (anemia, leukopenia, thrombocytopenia)
CONTRAINDICATIONS AND CAUTIONS
  • Type 1 diabetes mellitus
  • Diabetic ketoacidosis (DKA)
  • Pregnancy and breastfeeding
  • Children or elderly clients
  • Thyroid, cardiac, hepatic, or renal disease
NURSING CONSIDERATIONS: SULFONYLUREAS & MEGLITINIDES
ASSESSMENT AND MONITORING
Sulfonylureas and meglitinides
Assess
  • Laboratory test results, including CBC, blood glucose, hemoglobin A1c, electrolytes, renal and hepatic function

Monitor
  • Side effects and therapeutic response: blood glucose, hemoglobin A1c levels, CBC, liver and renal function tests
CLIENT EDUCATION
Sulfonylureas and meglitinides
  • Purpose of medication: lowers blood glucose levels by increasing insulin release from pancreas
  • Continue antidiabetic regimen: low-carbohydrate and high-fiber diet, regular physical activity, frequent blood glucose monitoring
  • Timing of medication administration with meals
    • Glipizide: take 30 minutes before the first meal of the day
    • Repaglinide: take within 30 minutes of each meal; do not take if a meal is skipped
  • Recognize side effects
    • Nausea, vomiting, headaches, joint pain
    • Hyperglycemia: fatigue, blurred vision; increased thirst, appetite, and urination
      • Check glucose level
      • Contact healthcare provider
    • Hypoglycemia: hunger, headache, fatigue, tremors, dizziness, confusion
      • Check blood glucose level
      • Consume a source of glucose; e.g., half a cup of orange juice, three glucose tablets, or approximately 15 grams of sugar
      • Check blood glucose after 15 minutes
    • Lactic acidosis: hyperventilation, muscle pain, and changes in their level of consciousness
      • Contact healthcare provider
      • Avoid alcohol

Transcript

Watch video only

Sulfonylureas and meglitinides are medications used to treat type 2 diabetes mellitus. Type 2 diabetes is characterized by insulin resistance, which is when tissue cells have trouble responding to insulin in order to use glucose from the blood.

As a result, tissue cells starve for energy despite having high blood glucose levels, which is called hyperglycemia.

Now, sulfonylureas can be classified into first and second generation, and are easy to recognize because they all have the suffix -ide.

First generation sulfonylureas include tolbutamide, which is short-acting, tolazamide, which is intermediate-acting, and chlorpropamide, which is long-acting; while second generation sulfonylureas include glimepiride, glipizide and glyburide

On the other hand, meglitinides have the suffix -glinide, and the most commonly used ones include repaglinide and nateglinide.

Okay, now both sulfonylureas and meglitinides are given orally and once administered, they both act on the pancreas by inhibiting ATP-sensitive potassium channels on the membrane of pancreatic beta cells.

As a result, these medications initiate a cascade of events that stimulate the pancreatic beta cells to secrete more insulin, ultimately leading to a decrease in blood glucose levels.

Fuentes

  1. "Focus on Nursing Pharmacology" LWW (2019)
  2. "Pharmacology" Elsevier Health Sciences (2014)
  3. "Mosby's 2021 Nursing Drug Reference" Mosby (2020)
  4. "Saunders Comprehensive Review for the NCLEX-RN Examination" Saunders (2016)
Elsevier

Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.

RELX